公开(公告)号：US08809385B2

公开(公告)日：2014-08-19

申请号：US12488079

申请日：2009-06-19

申请人： Steven J. Mehrman ,  Wenju Wu

发明人： Steven J. Mehrman ,  Wenju Wu

IPC分类号： A61K31/357 ,  C07D319/20

CPC分类号： C07D319/20

摘要： The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.

摘要翻译： 本发明涉及（2S） - （ - ） - N-（6-氯-2,3-二氢 - 苯并[1,4]二氧杂环己烯-2-基甲基） - 磺酰胺的新结晶形式，其含有 所述结晶形式和所述结晶形式用于治疗焦虑和相关疾病; 双相抑郁症和躁狂症; 萧条; 癫痫和相关疾病; 癫痫发生; 葡萄糖相关疾病; 脂质相关疾病; 偏头痛 肥胖; 疼痛; 药物滥用 或用于神经保护。 本发明进一步涉及制备新型结晶形式的方法。

公开(公告)号：US20090318544A1

公开(公告)日：2009-12-24

申请号：US12488079

申请日：2009-06-19

申请人： Steven J. Mehrman ,  Wenju Wu

发明人： Steven J. Mehrman ,  Wenju Wu

IPC分类号： A61K31/357 ,  C07D319/16 ,  A61P25/24 ,  A61P3/04 ,  A61P25/30 ,  A61P25/00

CPC分类号： C07D319/20

摘要： The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.

摘要翻译： 本发明涉及（2S） - （ - ） - N-（6-氯-2,3-二氢 - 苯并[1,4]二氧杂环己烯-2-基甲基） - 磺酰胺的新结晶形式，其含有 所述结晶形式和所述结晶形式用于治疗焦虑和相关疾病; 双相抑郁症和躁狂症; 萧条; 癫痫和相关疾病; 癫痫发生; 葡萄糖相关疾病; 脂质相关疾病; 偏头痛 肥胖; 疼痛; 药物滥用 或用于神经保护。 本发明进一步涉及制备新型结晶形式的方法。

公开(公告)号：US20110015215A1

公开(公告)日：2011-01-20

申请号：US12783913

申请日：2010-05-20

申请人： Paul Deghetto ,  Nagy E. Fawzy ,  Gary Fech ,  Kenneth M. Wells ,  Wenju Wu

发明人： Paul Deghetto ,  Nagy E. Fawzy ,  Gary Fech ,  Kenneth M. Wells ,  Wenju Wu

IPC分类号： A61K31/506 ,  C07D401/14 ,  A61P3/10 ,  A61P3/00 ,  A61P3/06 ,  A61P3/04

CPC分类号： C07D401/14

摘要： The present invention is directed to a novel crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutical compositions containing said crystalline form and the use of said crystalline forms in the treatment of metabolic related disorders. The present invention is further directed to processes for the preparation of the crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester.

摘要翻译： 本发明涉及4- [6-（6-甲磺酰基-2-甲基 - 吡啶-3-基氨基）-5-甲氧基 - 嘧啶-4-基氧基] - 哌啶-1-甲酸异丙基 酯，含有所述结晶形式的药物组合物和所述结晶形式用于治疗代谢相关疾病的用途。 本发明进一步涉及制备4- [6-（6-甲磺酰基-2-甲基 - 吡啶-3-基氨基）-5-甲氧基 - 嘧啶-4-基氧基] - 哌啶-4-甲酸的结晶形式的方法， 1-羧酸异丙酯。

公开(公告)号：US20070173490A1

公开(公告)日：2007-07-26

申请号：US11624292

申请日：2007-01-18

申请人： Lian Huang ,  Wenju Wu

发明人： Lian Huang ,  Wenju Wu

IPC分类号： A61K31/55 ,  C07D223/14

CPC分类号： C07D233/32 ,  C07D223/32

摘要： The present invention relates to novel solid forms of (4R)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4H-1-benzazepine-4,1′-[2]cyclopentene]-3′-carboxylic acid (formula (I)) useful for treating and/or preventing conditions such as diabetic nephropathy, renal disease, renal failure and congestive heart failure.

摘要翻译： 本发明涉及新的固体形式的（4R）-1- [4-（2-氯-5-氟苯甲酰基）氨基-3-甲氧基苯甲酰基] -1,2,3,5-四氢 - 螺[4H- 苯并吖庚因-4,1' - [2]环戊烯] -3'-羧酸（式（I）），其可用于治疗和/或预防糖尿病肾病，肾病，肾衰竭和充血性心力衰竭等病症。